Literature DB >> 15206584

Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs.

Kazumasa Yamashita1, Hideaki Yada, Toshihiko Ariyoshi.   

Abstract

In order to clarify the mechanism of the neurotoxicity of 5-FU and/or its masked compounds, we studied the effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on the formation of vacuolar changes in the dog cerebrum, using the dosage of 3.0 mg/kg/day of FBAL-HCl (FBAL x HCl) and 0.03 mg/kg/day of FA-Na (FA x Na), respectively. These 2 compounds were selected because they are the metabolites of 5-FU claimed to be responsible for the neurotoxic effects of 5-FU and/or its masked compounds, and we wanted to confirm their effects. Tegafur-uracil mixture (UFT) was used as a positive control drug for the formation of vacuolar changes in the dog cerebrum. All compounds were orally administered daily for 3 months to beagle dogs. Each study group consisted of 3 males. Neurotoxic signs such as hyperesthesia and/or excitement, as well as convulsions, were observed in both FBAL x HCl and FA x Na groups; these toxic signs were also found in the UFT group. Slight loss of body weight gain and of food consumption was observed in the FBAL x HCl and UFT groups. Neuropathologically, vacuolar changes were detected in several areas of the dog cerebrum following administration of FBAL x HCl, FA x Na or UFT. In terms of morphology, the neuropathological effects of these 2 drugs were very similar to those induced by UFT. In conclusion, we clearly showed that FBAL is one of the main substances that cause neurotoxic signs and neuropathological changes in dogs intoxicated by 5-FU or its masked compounds. Moreover, FA might be considered to be a causative factor in addition to FBAL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206584     DOI: 10.2131/jts.29.155

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  6 in total

1.  Seizures following subconjunctival 5-FU therapy.

Authors:  René Hoehn; Julia Lamparter; Norbert Pfeiffer; Urs Vossmerbaeumer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

Review 2.  The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Authors:  William H Gmeiner; Waldemar Debinski; Carol Milligan; David Caudell; Timothy S Pardee
Journal:  Future Oncol       Date:  2016-06-09       Impact factor: 3.404

Review 3.  Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.

Authors:  Frederik E Stuurman; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

4.  Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates.

Authors:  Ryuichi Nishii; William Tong; Richard Wendt; Suren Soghomonyan; Uday Mukhopadhyay; Julius Balatoni; Osama Mawlawi; Luc Bidaut; Peggy Tinkey; Agatha Borne; Mian Alauddin; Carlos Gonzalez-Lepera; Bijun Yang; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 5.  Chemical Aspects of Human and Environmental Overload with Fluorine.

Authors:  Jianlin Han; Loránd Kiss; Haibo Mei; Attila Márió Remete; Maja Ponikvar-Svet; Daniel Mark Sedgwick; Raquel Roman; Santos Fustero; Hiroki Moriwaki; Vadim A Soloshonok
Journal:  Chem Rev       Date:  2021-03-16       Impact factor: 60.622

6.  Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors.

Authors:  William H Gmeiner; Carla Lema-Tome; Denise Gibo; Jamie Jennings-Gee; Carol Milligan; Waldemar Debinski
Journal:  J Neurooncol       Date:  2013-12-18       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.